DC
TSHA icon

Diametric Capital’s Taysha Gene Therapies TSHA Stock Holding History

Diametric Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-512,361
Closed -$1.15M – 500
2024
Q2 		$1.15M Buy
512,361
+358,883
+234% +$1.04M 0.62% 35
2024
Q1 		$440K Buy
153,478
+84,607
+123% +$176K 0.24% 96
2023
Q4 		$122K Sell
68,871
-691,143
-91% -$1.38M 0.07% 221
2023
Q3 		$2.4M Buy
+760,014
New +$1.42M 1% 15

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Diametric Capital's TSHA Position: Q3 2024 in Review

Diametric Capital sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 512,361 shares — an estimated $1.15M sold.

Diametric Capital first reported a position in TSHA in Q3 2023 and held it in 4 quarters. The position peaked at $2.4M in Q3 2023. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Diametric Capital reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • Diametric Capital sold 512,361 Taysha Gene Therapies shares in Q3 2024, an estimated $1.15M.
  • Diametric Capital first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 4 quarters.
  • Diametric Capital's Taysha Gene Therapies position peaked at $2.4M in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Diametric Capital's 13F filing for Q3 2024, filed 13 Nov 2024.